1 / 15

Patterns of Care in Medical Oncology

Patterns of Care in Medical Oncology. Adjuvant Systemic Therapy for Colon Cancer. Approximately what percent of your patients with Stage II colon cancer receive adjuvant chemotherapy?.

amory
Download Presentation

Patterns of Care in Medical Oncology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Patterns of Care in Medical Oncology Adjuvant Systemic Therapy for Colon Cancer

  2. Approximately what percent of your patients with Stage II colon cancer receive adjuvant chemotherapy?

  3. Phase III randomized study of oxaliplatin, leucovorin calcium and fluorouracil with or without bevacizumabin patients with resected Stage II colon cancer Protocol ID: ECOG-E5202 Target Accrual: 3,610 (Open) FOLFOX Eligibility Stage II (T3-4, N0, M0) with paraffin-embedded tumor specimen available R High risk* FOLFOX + bevacizumab Low risk* Observation * Patients are stratified according to disease stage (IIA versus IIB), microsatellite stability status (microsatellite stable [MSS] or microsatellite instable [MSI]) and presence or absence of heterozygosity at chromosome 18q. Patients deemed to be at high risk based on these molecular parameters are randomly assigned to one of two treatment arms (arms I and II), whereas patients at low risk are assigned to arm III.

  4. Phase III randomized study of oxaliplatin, leucovorin calcium and fluorouracil with or without bevacizumabin patients with resected Stage II colon cancer Study Contacts Eastern Cooperative Oncology Group Al Benson, MD, FACP, Protocol Chair Tel: 312-695-6180 Peter O’Dwyer, MD, BCh, Protocol Co-Chair Tel: 215-662-7606 Email: peter.odwyer@uphs.upenn.edu Source: NCI Physician Data Query, November 2008.

  5. Have you used Peter Ravdin’s Adjuvant! Online programfor colon cancer?

  6. Approximately what percent of your patients with Stage II and III colon cancer do you think have a solid understanding of the following after consulting with you?

  7. Which of the following, if any, is your preferred 5-FU + leucovorin + oxaliplatin regimen in the adjuvant setting?

  8. When administering oxaliplatin-containing chemotherapy in the adjuvant setting, how often do you generally administer intravenous calcium and magnesium for neuroprotection?

  9. Case 1: Adjuvant Therapy for Patients with Stage III Colon Cancer • Woman in average health • T3 tumor in the left descending colon • 15/25 lymph nodes positive

  10. Case 1: Adjuvant Therapy for Patients with Stage III Colon Cancer • Woman in average health • T3 tumor in the left descending colon • 15/25 lymph nodes positive

  11. Have you used bevacizumab off protocol in the adjuvant setting?

  12. AVANT adjuvant study: A Phase III randomized trial comparing FOLFOX to FOLFOX with bevacizumab to CAPOX with bevacizumab in patients with resected colon cancer Target Accrual: 3,450 (Closed) Protocol IDs: UCLA-0412086-01, ROCHE-BO17920A, NCT00112918 FOLFOX x 6 months Eligibility High-risk Stage II orIII colon cancer • Curative surgery within the past four to eight weeks • No clinically significant cardiovascular disease* [FOLFOX + bevacizumab] x6 months followed bybevacizumab x 6 months R [CAPOX + bevacizumab] x6 months followed bybevacizumab x 6 months * Cerebrovascular accident within the past six months; myocardial infarction within the past year; uncontrolled hypertension while on chronic medication; unstable angina; NYHA Class II-IV heart failure; serious cardiac arrhythmias that require medication. A cardiac monitoring plan is included in this study.

  13. AVANT adjuvant study: A Phase III randomized trial comparing FOLFOX to FOLFOX with bevacizumab to CAPOX with bevacizumab in patients with resected colon cancer Study Contact Joel Hecht, MD Tel: 888-798-0719 Source: NCI Physician Data Query, November 2008.

  14. Practicing oncologists should be discussing the potential impact on risk of recurrence of the following with patients diagnosed with colon cancer:

  15. Practicing oncologists should be discussing the potential impact on risk of recurrence of the following with patients diagnosed with colon cancer:

More Related